estimating risk of BCR and risk of aggressive recurrence after RP was assessed using the concordance index, c .
RESULTS
The 10-year risks of BCR and aggressive recurrence were 47% and 9%, respectively. Across all nine models tested, the PA was a mean (range) of 0.054 (0.024-0.074) points higher for predicting aggressive recurrence than for predicting BCR alone ( c = 0.756 vs 0.702). Similar results were obtained in four sensitivity analyses: (i) defining patients with BCR but unavailable PSADT (220) as having aggressive recurrence; (ii) defining these patients as not having aggressive recurrence; (iii) defining aggressive recurrence as a PSADT of < 6 months; or (iv) defining aggressive recurrence as a PSADT of < 12 months. The improvement in PA was greater for preoperative than for postoperative models (0.053 vs 0.036, P = 0.03).
CONCLUSION
Across nine different models the prediction of aggressive recurrence after RP was more accurate than the prediction of BCR alone. This is probably because current models mainly assess cancer biology, which correlates better with aggressive recurrence than with BCR alone. Overall, all models had relatively similar accuracy for predicting aggressive recurrence.
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OBJECTIVE
To compare the predictive accuracy (PA) of existing models in estimating risk of biochemical recurrence (BCR) vs aggressive recurrence (BCR with a prostate-specific antigen, PSA, doubling time, DT, of < 9 months).
PATIENTS AND METHODS
The study included 1550 men treated with radical prostatectomy (RP) between 1988 and 2007 within the Shared Equal Access Regional Cancer Hospital database. The PA of nine different risk stratification models for
INTRODUCTION
Despite early detection and aggressive intervention, a third of men will develop a biochemical recurrence (BCR) after radical prostatectomy (RP) for prostate cancer [1, 2] . Ultimately, there are two major reasons why men might have BCR after RP. The first is advanced stage and aggressive disease (i.e. 'poor biology'); the second is poor surgical technique. We hypothesized that men who develop a recurrence due to poor technique alone in the absence of poor biology are less likely to have an aggressive recurrence. Alternatively, men who have an aggressive recurrence probably have poor biology. As such, much effort has been put into developing nomograms and risk-stratification tools to identify men who are likely to develop BCR [3] [4] [5] [6] [7] [8] [9] . However, these models use almost exclusively variables associated with cancer biology, e.g. stage, grade and PSA level [10] . Therefore, we hypothesized that currently available models, which in fact estimate 'poor biology', will predict aggressive recurrence with greater accuracy than overall recurrence. Fortunately, aggressive disease can be identified early in the disease course, based on a short PSA doubling time (PSADT) after RP [11] [12] [13] . Indeed, although the time to PSA recurrence correlates with prostate cancerspecific survival [14] , it is not a surrogate for death from cancer. On the contrary, a very short PSADT is a surrogate for death from prostate cancer [11] . However, whether currently available nomograms designed to predict BCR predict the more clinically relevant endpoint of aggressive recurrence defined by a short PSADT is unknown.
To test this, we used seven different previously published models as well as basic pre-and postoperative models that include preoperative PSA level, stage and grade, and assessed their ability to predict an aggressive recurrence (i.e. recurrence with a PSADT after RP of < 9 months) vs their ability to predict any BCR among men undergoing RP within the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
PATIENTS AND METHODS
After obtaining institutional review board approval from each institution to abstract and combine data, we combined data from patients undergoing RP between 1988 and 2007 at the Veterans Affairs Medical Centers in West Los Angeles and Palo Alto, California, Augusta, Georgia, and Durham, North Carolina into the SEARCH database [15] . Patients treated with androgen deprivation or radiotherapy before RP were excluded. Men with missing follow-up data (59) or recurrence data (two) could not be classified and were therefore excluded. As a recent history of previous TURP is likely to significantly lower the preoperative PSA levels, men with clinical stage T1a or T1b (46) were excluded. Because men with node-positive disease are likely to harbour aggressive disease and are at high-risk of death from prostate cancer, they were also excluded (23) . We also excluded 54 and 13 men with missing preoperative PSA data or data for Gleason scores before and after RP, respectively, resulting in a study population of 1550 men.
BCR was defined as one PSA level of > 0.2 ng/ mL, two of 0.2 ng/mL, or secondary treatment for an elevated and/or rising PSA level after RP. Men who received adjuvant treatment and with an undetectable PSA level were censored as 'no recurrence' at the time of treatment. The PSADT was calculated by dividing log n 2 (0.693) by the slope of the linear regression line of log n PSA level over time [16] . The PSADT was computed for all patients meeting the recurrence definition who had a minimum of two PSA values, separated by ≥ 3 months, and at < 2 years after recurrence. All PSA values within the first 2 years after recurrence were used to calculate the PSADT. For patients starting salvage hormone or radiotherapy within this time, only PSA values before salvage therapy were used. Therefore, all PSA values used were ≥ 0.2 ng/mL and obtained before subsequent treatment. Patients with a decline or no change in PSA level, or with a very long PSADT ( > 100 months) were assigned a value of 100 months for ease of calculations (51 men).
We defined a priori an aggressive recurrence as recurrence with a PSADT of < 9 months, based on the high prostate cancer-specific mortality in a previous study [12] . Patients with no BCR were censored as not having an aggressive recurrence at the time of the last follow-up. Patients with BCR but a PSADT of ≥ 9 months were censored as not having an aggressive recurrence at the time of their recurrence, as these men were at low risk of death from prostate cancer in a previous study [12] .
The predictive accuracy (PA) of multiple risk stratification models for estimating the risk of BCR and risk of aggressive recurrence after RP was assessed by calculating Harrell's concordance index c for each of these models for both endpoints. . Thus, none of the previously published models were developed based on data from the SEARCH database.
For our basic clinical and pathological models, we determined the risk of overall recurrence using a multivariate Cox proportional hazards model with only the variables described above included. Each patient was then assigned a risk score that was equivalent to the sum of the regression coefficients from the multivariate Cox model. This risk score was then assessed as a single continuous variable.
For all other models we used the respective published formulae to calculate continuous risk scores for each patient.
Patients (220) who had a BCR but missing PSADT were excluded from the primary analysis. However, sensitivity analyses were conducted redefining these patients as (i) having aggressive recurrence at the time of BCR or (ii) as remaining with no aggressive recurrence at the time of BCR and therefore censoring them at the time of BCR. Further sensitivity analyses used different thresholds for PSADT ( < 6 and < 12 months) to define aggressive recurrence. A threshold of < 3 months was not tested, as only 13 patients recurred with a PSADT of < 3 months.
Kaplan-Meier survival curves were plotted for the cohort using BCR and aggressive recurrence as the event. For all statistical analysis we used STATA 9.2 (STATACorp, College Station, TX, USA) and R 2.5.1 [18] with the packages 'Hmisc' and 'Design' [19] .
RESULTS
The clinicopathological variables of the study population are described in Table 1 ; ≈ 40% of the patients had low-risk, 41% intermediaterisk and 20% high-risk disease, by the classification of D'Amico et al. [3] . The median follow-up among patients with no recurrence was 52 months, during which 522 patients (34%) had BCR. Patients with BCR tended to have higher risk disease compared to the entire cohort (Table 1) . Only 86 patients (7% of all patients and 29% of the 302 with a BCR and PSADT available) had an aggressive recurrence according to our definition. Figure  1 shows the recurrence-free survival curves for the endpoints of BCR and aggressive recurrence. The risks (95% CI) of overall and aggressive recurrence at 10 years were 47 (43-50)% and 9 (7-12)%, respectively. Among men who had a BCR, the median time to BCR was 17 months, whereas among those who had an aggressive recurrence, the median time to recurrence was 9 months. The median PSADTs for patients with aggressive and no aggressive recurrence were 5 and 23 months, respectively.
The PA (Harrell's c ) for estimating the risk of BCR and aggressive recurrence is shown in Table 2 for all nine models tested. The best performing models for predicting BCR and aggressive recurrence in these patients were the Duke Prostate Center model ( c = 0.748) and the postoperative Kattan nomogram ( c = 0.777), respectively. Overall, all models worked reasonably well for predicting BCR, with a difference in PA between the best and worst model of 0.088. For all nine models, Harrell's c was higher (mean 0.054, range 0.024-0.074) for predicting aggressive recurrence than for predicting BCR alone. Moreover, the PA of all the models for estimating the risk of aggressive recurrence was quite good, with a narrower range such that the difference between the best and worst model was only 0.049.
As 220 men had BCR but no PSADT available, they were unable to be classified and therefore were excluded from our primary analysis. However, we conducted sensitivity analyses in which these men were included but classified as having an aggressive recurrence. Using this approach, all nine models still performed a mean (range) of 0.017 (0.004-0.043) better in predicting aggressive recurrence than BCR (data not shown). When these 220 men were included but censored as not having an aggressive recurrence, Harrell's c was 0.053 (0.022-0.083) higher for all nine models for predicting aggressive recurrence than BCR (data not shown).
Further sensitivity analyses using thresholds of < 12 and < 6 months for defining aggressive recurrence gave a high mean PA of all nine models for estimating the risk of aggressive recurrence, and similar across all three definitions ( c = 0.756, 0.742 and 0.739 for thresholds of < 9, < 12 and < 6 months, respectively). Again, all models performed a mean of 0.040 (0.017-0.057) better in predicting aggressive recurrence vs BCR alone when < 12 months was used (data not shown). All but one model (the Duke Prostate Center model [6]) performed better, by a mean (range) of 0.037 (-0.011, 0.071) when < 6 months was used (data not shown). Across all three definitions of aggressive recurrence (i.e. PSADT < 6, < 9 or < 12 months), preoperative models had a significantly better improvement in PA than postoperative models for estimating aggressive recurrence relative to their ability to predict BCR alone (0.053 vs 0.036 improvement, Wilcoxon ranksum P = 0.03).
DISCUSSION
The existing models designed to estimate the risk of BCR had a greater PA for estimating the risk of aggressive recurrence than for estimating the risk of BCR. In our main analysis, the nine models tested were a mean of 5.4% more accurate in estimating the risk of aggressive recurrence than of BCR. Overall, the improvement in PA for aggressive recurrence vs BCR was highest for models that were based only on preoperative characteristics. As a very short PSADT is a surrogate for death from prostate cancer [11], the current findings are encouraging, in that all models tested performed well at predicting these life-threatening aggressive recurrences. Previous studies have shown that not all men with BCR are at high risk of death from prostate cancer. For example, previous studies found that the overall 10-year survival is only 20-30% for men with a PSADT of < 3 months, compared with > 90% for men with a PSADT of ≥ 15 months [11, 13] . Although aggressive disease can be identified relatively early in the disease course, based on a short postoperative PSADT [11] [12] [13] , it is most important to predict clinically relevant recurrences (i.e. those with a short PSADT that are most likely to progress) before BCR, to identify candidates for adjuvant therapy and clinical trials. Unfortunately, most models currently used were designed to predict BCR, not specifically high-risk BCR. However, given the findings of the present study, an individual predicted to be at significant risk of BCR based on a currently available nomogram will also be at higher risk of aggressive recurrence.
We hypothesized that men who had a BCR as a result of poor surgical technique are less likely to have an aggressive recurrence, and conversely that aggressive recurrences are strongly influenced by unfavourable cancer biology. Our main finding supported this hypothesis. Specifically, the nine models tested, which all included primarily biologyrelated variables (i.e. PSA level, stage and grade), were more accurate in predicting aggressive recurrence vs any BCR. Indeed, a previous study also found factors mainly representing aggressive cancer biology (i.e. high-risk disease before RP and a RP Gleason score of 8-10, seminal vesicle invasion, or a time to PSA failure of < 2 years after RP) to be independently predictive of a short PSADT after BCR [20] . Similarly, a recent study from the SEARCH database group found that only PSA level, pathological findings and RP Gleason grade were independently associated with aggressive recurrence [21] . Finally, yet another study found a rapid preoperative PSA velocity, a strong predictor of death from cancer, was associated with an aggressive recurrence [22] . Notably, in a follow-up to the latter study, a high PSA velocity, while helpful for predicting any BCR, was a much better discriminator of who would die from prostate cancer (i.e. have the most aggressive form of the disease) [23] . Thus, it appears that aggressive recurrences are most driven by 'poor biology' .
Overall, the mean PA of the models was highest when < 9 months was chosen as the definition for aggressive recurrence, which might imply that this is the best definition for aggressive recurrence. Indeed, one previous study also suggested that a 9-month PSADT threshold might best discriminate between fatal and more indolent prostate cancer [13] . However, further studies focusing specifically on this question are needed to ultimately find the ideal PSADT threshold for defining aggressive recurrence.
To examine the robustness of our findings, we used several sensitivity analyses, and found that all models (with the exception of one when aggressive recurrence was defined as a PSADT of < 6 months) performed better when the outcome of interest was aggressive recurrence rather than BCR. Thus, whether the 220 men with recurrence but missing PSADT were excluded, considered as having an aggressive, or non-aggressive recurrence, and whether aggressive recurrence was defined using a PSADT threshold of < 6, < 9 or < 12 months, the PA was better for estimating the risk of aggressive recurrence relative to overall BCR. However, ultimately these results require validation in other datasets using more distant endpoints such as metastasis and prostate cancer-specific death.
One strength of our study was a parallel comparison and external validation of seven previously published models. The best model for defining the risk of BCR in this cohort was the model recently developed by our group using the independent Duke Prostate Center database [6] . Its PA was nearly identical to the PA described in the initial report [6] . Thus, the present study is the first to independently validate the usefulness of this model. Moreover, this model also worked well to predict aggressive recurrence.
Overall, the differences among all the models in the PA for any BCR were modest. Differences among the various models for estimating the risk of aggressive recurrence were even less pronounced, with a narrower range of PAs. The best model in this setting was the postoperative nomogram of Kattan et al. [5] , but the other models performed only marginally worse. It therefore appears that the PA in itself might not be the most important factor in choosing a model for clinical use, due to the overall similarity in performance across many models. Moreover, while validation is essential [10], the current study was able to equally well validate all external models. Therefore, it seems reasonable to base the choice of which model to use on personal preference and ease of use [24] .
One limitation of the current study is the overall high positive margin rate and high 10-year BCR rate. The degree to which this influenced the ratio of biology-driven vs poor technique-driven recurrences is unknown. Invariably, in a population of predominantly technique-driven recurrences, we would hypothesise that the improvement in model performance for predicting aggressive recurrence vs any BCR would be greater. As such, the percentage of men who had an aggressive recurrence among those who recurred in the present study (29% using our definition) was similar to that in previous studies (38% with a PSADT of < 9 months [12] and 38% with a PSADT of < 12 months [25] ). Moreover, other characteristics of our patients with BCR (Table 1) are also comparable to previously published series [12, 25] . This suggests the ratio of biology- Another limitation is that 220 patients had BCR but no PSADT available. Although we excluded these patients from our primary analysis and performed sensitivity analyses assuming these patients were either free of aggressive disease or recurred with aggressive disease, it is possible that missing PSADT values affected our results. Therefore, our results require validation in independent datasets.
We found that the PA of existing models was higher when aggressive recurrence was used as the outcome of interest. However, this outcome is fortunately relatively rare. The 10-year risk of aggressive recurrence in the current cohort was only 9%. Therefore, the risks of BCR after RP obtained from current nomograms or risk calculators cannot be directly transferred into risks of aggressive recurrence. For this endpoint, new risk estimates based on existing patient populations with available PSADT after BCR would need to be calculated. Nevertheless our results are encouraging, as in clinical use it will probably be more important to identify patients at relatively high risk of aggressive recurrence who would be candidates for adjuvant therapy trials, than to identify patients who are at risk of BCR alone. The current findings suggest that this might be done using currently existing nomograms, and with even greater accuracy than predicting any BCR, provided the baseline risks used in these nomograms are adjusted to the overall much lower risk of an aggressive recurrence.
In conclusion, using seven different previously published models, as well as a simple pre-and postoperative models developed in this patient cohort, we found the prediction of aggressive recurrence after RP was more accurate than predicting BCR alone. This is probably because current models mainly measure cancer biology, which correlates better with aggressive recurrence than with BCR alone.
